Aneuvo's FDA clearance and prior CE mark for ExaStim make it one of the few transcutaneous SCS companies with both regulatory approval and home-use indication rather than clinic-only trial data. Its patent dispute with Onward Medical, resolved in Aneuvo's favor at the Unified Patent Court, signals a competitive and increasingly commercial transcutaneous stimulation market rather than a purely early-research field.